The trajectory of Sildenafil presents a challenging picture for investors. While the initial release generated significant returns, the end of its exclusive rights opened the floodgates to generic competitors, dramatically diminishing revenue. This presents a unique dilemma for pharmaceutical companies relying on similar blockbuster offerings, sugg

The history of Viagra, and its parent company copyright, presents a challenging case study for investors. Originally a blockbuster drug, producing billions in income, its intellectual property lapse created a wave of knock-off medications, significantly impacting its market share . While specific firms may attempt to capitalize on similar condition